Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys

Annals of Neurology
T KandaP Jenner

Abstract

Treatment of Parkinson's disease with L-dopa therapy leads to long-term complications, including loss of drug efficacy and the onset of dyskinesia. Adenosine A2A receptors in striatum are selectively localized to GABAergic output neurons of the striato-pallidal pathway and may avoid such problems. The novel adenosine A2A receptor antagonist KW-6002 has been examined for antiparkinsonian activity in MPTP-treated primates. Oral administration of KW-6002 reversed motor disability in MPTP-treated common marmosets in a dose-dependent manner. However, KW-6002 only modestly increased overall locomotor activity and did not cause abnormal movement, such as stereotypy. The ability of KW-6002 to reverse motor disability was maintained on repeated daily administration for 21 days, and no tolerance was observed. KW-6002 induced little or no dyskinesia in MPTP-treated primates previously primed to exhibit dyskinesia by prior exposure to L-dopa. These results suggest that selective adenosine A2A receptor antagonists represent a new class of antiparkinsonian agents that improve disability without producing hyperactivity and without inducing dyskinesia.

References

Sep 16, 1991·Neuroscience Letters·S FerréK Fuxe
Sep 16, 1991·Neuroscience Letters·S N SchiffmannJ J Vanderhaeghen
May 1, 1991·Pharmacology, Biochemistry, and Behavior·S A Josselyn, R J Beninger
May 1, 1989·Annals of Neurology·M M MouradianT N Chase
Jan 1, 1987·Movement Disorders : Official Journal of the Movement Disorder Society·N QuinnC D Marsden
Sep 1, 1994·British Journal of Pharmacology·M KurokawaP J Richardson
Jun 1, 1994·The Journal of Pharmacy and Pharmacology·J Mally, T W Stone
May 2, 1994·European Journal of Pharmacology·T KandaJ Nakamura
Jan 1, 1995·Fundamental & Clinical Pharmacology·P J BlanchetP J Bédard
Dec 1, 1995·Trends in Neurosciences·Y KawaguchiP C Emson
Nov 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·R K PearceC D Marsden
Jan 1, 1996·Movement Disorders : Official Journal of the Movement Disorder Society·P J BlanchetP J Bédard
May 1, 1996·Journal of Neurochemistry·M KurokawaY Kuwana
Nov 5, 1997·Trends in Pharmacological Sciences·P J RichardsonP G Jenner

❮ Previous
Next ❯

Citations

Jul 3, 2013·Naunyn-Schmiedeberg's Archives of Pharmacology·Mayumi SakiTomoyuki Kanda
Apr 29, 2008·Purinergic Signalling·Marek CieślakAndrzej Wojtczak
Jun 12, 2009·Current Neurology and Neuroscience Reports·James B KoprichJonathan M Brotchie
May 16, 2012·Current Neurology and Neuroscience Reports·Patrick Hickey, Mark Stacy
Apr 23, 2009·Neurotoxicity Research·Krystyna GołembiowskaKatarzyna Kamińska
May 24, 2013·Drugs·Rosselle Dungo, Emma D Deeks
Dec 27, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Jacobus P PetzerCornelis J Van der Schyf
Oct 1, 2010·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Phillip M Rappold, Kim Tieu
Oct 21, 2000·European Journal of Pharmacology·L HalldnerB B Fredholm
Jul 6, 2002·European Journal of Pharmacology·Annalisa PinnaMicaela Morelli
Feb 26, 2003·European Journal of Pharmacology·Claudia CorsiFelicita Pedata
May 12, 2001·Il Farmaco·E OnginiP G Baraldi
Dec 28, 1999·Brain Research. Brain Research Reviews·J L Moreau, G Huber
May 17, 2003·European Journal of Medicinal Chemistry·Pier Giovanni BaraldiPier Andrea Borea
Feb 11, 2003·Progress in Neurobiology·J A RibeiroA de Mendonça
Sep 29, 1999·Progress in Neurobiology·P SvenningssonB B Fredholm
Mar 23, 2000·Progress in Neurobiology·P CalabresiG Bernardi
Aug 30, 2000·Neuroscience Letters·M J HurleyP Jenner
May 2, 2001·Parkinsonism & Related Disorders·S FerréK Fuxe
Oct 29, 2000·Trends in Neurosciences·T N Chase, J D Oh
Aug 4, 2012·ACS Chemical Neuroscience·Brian C Shook, Paul F Jackson
Oct 24, 2006·Nature Clinical Practice. Neurology·Carlo ColosimoAlfredo Berardelli
Oct 1, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yoland SmithMahlon R DeLong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.